Palbociclib Intermedia CAS 1013916-37-4 Puritas >99.0% (HPLC)

Description:

Nomen chemicum: 2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-unus

CAS: 1013916-37-4

Puritas: >99.0% (HPLC)

Aspectus: Fain Yellow Pulvis

Medium de Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Palbociclib Intermedia:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidines CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl) piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Nomen chemicum	2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-unus
Synonyma	2-Chloro-8-Cyclopentyl-5-Methylpyrido[2,3-d]pyrimidin-7(8H)-one;Palbociclib medium 2
CAS Number	1013916-37-4
CATTUS Number	RF-PI1847
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C13H14ClN3O
M. Pondus	263.72
Aqua Solubility	Leviter solutum in aqua
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Deficere Yellow pulveris
Puritas / Analysis Methodus	>99.0% (HPLC)
Humor (KF)	<0.50%
Residere in Ignition	<0.20%
Totalis immunditias	<1.00%
Test Standard	Enterprise Standard
Consuetudinem	Medium Palbociclib (CAS: 571190-30-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

2-Chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-unus (CAS: 1013916-37-4) adhibetur ut intermedium pharmaceuticum ex Palbociclib (CAS: 571190-30. -2).Palbociclib medicamentum est ad curationem carcinomatis ER-positivi et HER2-negativi carcinomatis effecti.Inhibitor selectivorum cyclini-dependens kinasium CDK4 et CDK6.Palbociclib primus CDK4/6 inhibitor fuit ut therapia cancri ab aliqua ordinatione approbaretur, et sicut Decembri 2017 praescriptum est plus quam 90.000 vicibus.